AWM
ITCI

Avior Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avior Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,119
Closed -$344K – 2448
2024
Q4 		$344K Sell
4,119
-354
-8% -$29.1K 0.01% 553
2024
Q3 		$327K Buy
4,473
+131
+3% +$9.85K 0.01% 561
2024
Q2 		$297K Buy
4,342
+4,324
+24,022% +$300K 0.01% 573
2024
Q1 		$1.25K Sell
18
-42
-70% -$2.89K ﹤0.01% 2357
2023
Q4 		$4.3K Hold
60
– – ﹤0.01% 1187
2023
Q3 		$3.13K Buy
60
+18
+43% +$1.05K ﹤0.01% 1321
2023
Q2 		$2.66K Hold
42
– – ﹤0.01% 1324
2023
Q1 		$2.27K Buy
+42
New +$2.03K ﹤0.01% 1382

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Avior Wealth Management's ITCI Position: Q1 2025 in Review

Avior Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,119 shares — an estimated $344K sold.

Avior Wealth Management first reported a position in ITCI in Q1 2023 and held it in 8 quarters. The position peaked at $344K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Avior Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 4,119 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $344K.
  • Avior Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 8 quarters.
  • Avior Wealth Management's Intra-Cellular Therapies Inc. position peaked at $344K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.